13 reports of this reaction
1.2% of all MEXILETINE HYDROCHLORIDE reports
#19 most reported adverse reaction
CATARACT is the #19 most commonly reported adverse reaction for MEXILETINE HYDROCHLORIDE, manufactured by ANI Pharmaceuticals, Inc.. There are 13 FDA adverse event reports linking MEXILETINE HYDROCHLORIDE to CATARACT. This represents approximately 1.2% of all 1,120 adverse event reports for this drug.
Patients taking MEXILETINE HYDROCHLORIDE who experience cataract should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CATARACT is a less commonly reported adverse event for MEXILETINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to cataract, the following adverse reactions have been reported for MEXILETINE HYDROCHLORIDE:
The following drugs have also been linked to cataract in FDA adverse event reports:
CATARACT has been reported as an adverse event in 13 FDA reports for MEXILETINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CATARACT accounts for approximately 1.2% of all adverse event reports for MEXILETINE HYDROCHLORIDE, making it a notable side effect.
If you experience cataract while taking MEXILETINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.